Sierra Oncology Inc (NASDAQ:SRRA) – Jefferies Financial Group boosted their Q2 2019 earnings estimates for shares of Sierra Oncology in a report released on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now expects that the biotechnology company will post earnings per share of ($0.19) for the quarter, up from their prior estimate of ($0.23). Jefferies Financial Group also issued estimates for Sierra Oncology’s Q3 2019 earnings at ($0.25) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($0.90) EPS, FY2020 earnings at ($1.01) EPS, FY2021 earnings at ($0.74) EPS, FY2022 earnings at ($0.49) EPS and FY2023 earnings at $0.27 EPS.
Sierra Oncology (NASDAQ:SRRA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.04.
Several other equities research analysts have also recently weighed in on SRRA. Wedbush reiterated an “outperform” rating on shares of Sierra Oncology in a report on Thursday, February 28th. Zacks Investment Research cut Sierra Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, March 21st.
Shares of SRRA stock opened at $1.46 on Thursday. Sierra Oncology has a twelve month low of $1.05 and a twelve month high of $3.70. The firm has a market capitalization of $109.04 million, a price-to-earnings ratio of -1.95 and a beta of 1.70. The company has a debt-to-equity ratio of 0.06, a current ratio of 13.07 and a quick ratio of 13.07.
Several hedge funds and other institutional investors have recently modified their holdings of SRRA. Renaissance Technologies LLC increased its position in Sierra Oncology by 27.5% during the 3rd quarter. Renaissance Technologies LLC now owns 2,252,244 shares of the biotechnology company’s stock valued at $3,829,000 after buying an additional 485,344 shares in the last quarter. Morgan Stanley grew its holdings in Sierra Oncology by 11.3% during the third quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock worth $1,687,000 after acquiring an additional 100,709 shares during the period. Hikari Power Ltd acquired a new stake in Sierra Oncology during the fourth quarter worth about $330,000. Acadian Asset Management LLC grew its holdings in Sierra Oncology by 5.4% during the fourth quarter. Acadian Asset Management LLC now owns 407,105 shares of the biotechnology company’s stock worth $538,000 after acquiring an additional 20,754 shares during the period. Finally, Broadfin Capital LLC grew its holdings in Sierra Oncology by 19.3% during the fourth quarter. Broadfin Capital LLC now owns 4,880,327 shares of the biotechnology company’s stock worth $6,442,000 after acquiring an additional 789,983 shares during the period. Hedge funds and other institutional investors own 64.56% of the company’s stock.
About Sierra Oncology
Sierra Oncology, Inc, a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.